Diagnosis and strategy for management of disseminated intravascular coagulation

1. What is it? Any common name for this procedure?

Disseminated Intravascular Coagulation (DIC) is not a primary disease but a life-threatening, systemic clinical-pathological syndrome characterized by widespread activation of the body's blood-clotting mechanism. In a healthy body, clotting is localized to a site of injury; in DIC, the process escapes control, causing small blood clots to form throughout the circulatory system. This results in two paradoxical problems: thrombosis (clotting) that blocks blood flow to vital organs, and hemorrhage (bleeding) because the body exhausts its supply of platelets and clotting factors.

Common Names/Synonyms:

• Consumptive Coagulopathy: Highlighting the "consumption" of clotting factors.
• Defibrination Syndrome: Referencing the depletion of fibrinogen.
• Disseminated Intravascular Coagulopathy.

2. Common Symptoms at Which One Must Meet the Doctor

DIC is a medical emergency that often presents in critically ill patients. You should seek immediate medical intervention if a patient with an underlying infection or injury exhibits:

• Unexplained Bleeding: Oozing from intravenous (IV) sites, surgical wounds, gums, or the nose.
• Skin Changes: The appearance of petechiae (tiny red spots), purpura (larger purple bruises), or skin necrosis (blackening of the skin).
• Organ Dysfunction: Signs of kidney failure (reduced urine), liver failure (jaundice), or lung failure (shortness of breath).
• Neurological Symptoms: Sudden confusion, altered consciousness, or seizures due to micro-clots in the brain.
• Circulatory Shock: Rapid heart rate, dangerously low blood pressure, and cold, clammy extremities.

3. List of Associated Diseases

DIC is always secondary to an underlying triggering condition that releases pro-coagulant substances into the blood. Common triggers include:

• Sepsis and Severe Infection: Particularly Gram-negative bacteria (the most common cause).
• Malignancy: Solid tumors (pancreatic, lung, prostate) and blood cancers like Acute Promyelocytic Leukemia (APL).
• Obstetric Complications: Abruptio placentae (placental abruption), amniotic fluid embolism, and pre-eclampsia.
• Massive Trauma: Severe head injuries, burns, or crush injuries.
• Severe Toxic Reactions: Certain snake venoms or major transfusion reactions.
• Acute Pancreatitis.

4. List of Screening Tests

Diagnosis relies on a combination of clinical suspicion and a "panel" of laboratory markers, as no single test is definitive.

Clinicians often use the ISTH Scoring System to categorize the severity; a score of 5 or higher indicates "Overt DIC".

5. Am I Eligible for This Procedure?

Eligibility for DIC management is determined by the presence of a known triggering condition combined with laboratory evidence of coagulopathy. Patients who are at high risk—such as those in the ICU with sepsis or women experiencing severe pregnancy complications—are continuously monitored for "non-overt" (early) signs of DIC. If the scoring system indicates a systemic failure of the coagulation system, the management protocol is immediately initiated.

6. Pre and Post Care for This Procedure

Management Strategy (Pre-Intervention):

The primary goal is the aggressive treatment of the underlying cause (e.g., surgical drainage of an abscess, delivery of a fetus, or broad-spectrum antibiotics for sepsis). Without resolving the trigger, blood products will simply be "consumed" as fast as they are infused.

Supportive Care (During/Post-Intervention):

• Blood Component Therapy: Infusion of Fresh Frozen Plasma (FFP) to replace clotting factors and Platelet Transfusion if levels are dangerously low and bleeding is present.
• Cryoprecipitate: Administered if fibrinogen levels fall below $1.0\text{ g/L}$.
• Anticoagulation: In specific cases where clotting (thrombosis) is the dominant feature, low-dose Heparin may be used cautiously.
• Continuous Monitoring: Laboratory tests (PT, PTT, Platelets) are often repeated every 6 to 12 hours to track the body’s response to therapy.

7. Days Required for Hospitalization

DIC management almost always occurs within an Intensive Care Unit (ICU) or a High Dependency Unit due to the need for continuous hemodynamic monitoring and frequent blood transfusions.

• Initial Stabilization: Typically requires 5 to 10 days in the ICU.
• Total Hospital Stay: Can range from 2 to 4 weeks, depending on the recovery of the organs (kidneys, lungs) affected by micro-clots.

Disclaimer: As per doctor’s advise the number of day’s may get modified based on the patient's individual response to treatment and the complexity of the underlying disease.

8. Benefits of This Procedure

• Restoration of Hemostasis: Halts the dangerous cycle of spontaneous bleeding and widespread clotting.
• Organ Preservation: By breaking down micro-thrombi, the protocol helps restore blood flow to the kidneys, liver, and lungs, preventing permanent organ failure.
• Survival Improvement: While DIC has a high mortality rate ($20\text{-}50\%$), timely management and treating the root cause significantly increase the chances of survival.
• Prevention of Secondary Complications: Reduces the risk of major strokes or pulmonary embolisms associated with the thrombotic phase of the syndrome.